This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
IMV to Develop Vaccine Candidate Against COVID-19, Shares Up
by Zacks Equity Research
IMV plans to develop a vaccine candidate using its lipid-based delivery platform, DPX technology, for the treatment of coronavirus disease. Stock rises.
Emergent (EBS) to Help Vaxart Develop Coronavirus Vaccine
by Zacks Equity Research
Emergent BioSolutions (EBS) teams up with Vaxart to support development of the latter's oral vaccine candidate for treating coronavirus disease.
Emergent (EBS) Begins Development of Treatments for COVID-19
by Zacks Equity Research
Emergent (EBS) starts developing two plasma-derived product candidates for the treatment and prevention of coronavirus disease.
Emergent BioSolutions Collaborates for Coronavirus Vaccine
by Zacks Equity Research
Emergent BioSolutions' (EBS) collaborates with Novavax to support production of the latter's coronavirus vaccine and advance it to clinical stage development.
Emergent (EBS) Earnings Miss in Q4, Revenues Beat Estimates
by Zacks Equity Research
Emergent's (EBS) earnings lag estimates in Q4 while revenues surpass the mark.
Emmaus (EMMA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors look forward to updates on key drug Endari's expansion plans when Emmaus (EMMA) releases fourth-quarter 2019 results.
Emergent (EBS) Posts Preliminary '19 Results, Gives 2020 View
by Zacks Equity Research
Emergent (EBS) narrows revenue view for 2019 and expects a consistent rise in Narcan nasal spray sales during 2020.
AMAG to Sell Women Healthcare Drugs, CEO Resigns, Stock Down
by Zacks Equity Research
AMAG's (AMAG) CEO will step down from the post once a successor is named. The company also plans to divest its women's healthcare drugs -- Intrarosa and Vyleesi.
Blueprint Medicines' Ayvakit Gets FDA Nod for Rare Cancer
by Zacks Equity Research
Blueprint Medicines (BPMC) gets its maiden FDA approval for its lead candidate Ayvakit to treat adult patients with PDGFRA Exon 18 mutant gastrointestinal stromal tumor (GIST).
Catabasis (CATB) Partners with UK-Based Charity for DMD Study
by Zacks Equity Research
Catabasis (CATB) teams up with Duchenne UK to fund a phase II study of its pipeline candidate edasalonexent, now being developed to treat patients with non-ambulatory Duchenne muscular dystrophy.
Blueprint Medicines Posts Data From NSCLC Study on Pralsetinib
by Zacks Equity Research
Blueprint Medicines (BPMC) posts top-line data from phase I/II study on pralsetinib to treat previously treated patients with RET-fusion NSCLC. Also, it initiates the rolling NDA submission to FDA.
Agenus Initiates Phase I Study on Oncology Candidate AGEN1223
by Zacks Equity Research
Agenus (AGEN) initiates phase I study on AGEN1223, a novel bi-specific antibody designed to deplete regulatory T cells in the tumor micro environment.
The Zacks Analyst Blog Highlights: H&R Block, Berry Global Group, Emergent BioSolutions, Pilgrim's Pride and Alexion Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: H&R Block, Berry Global Group, Emergent BioSolutions, Pilgrim's Pride and Alexion Pharmaceuticals
EBS vs. ILMN: Which Stock Is the Better Value Option?
by Zacks Equity Research
EBS vs. ILMN: Which Stock Is the Better Value Option?
Incyte's Application for Pemigatinib Gets EMA's Validation
by Zacks Equity Research
The EMA endorses Incyte's (INCY) MAA for pemigatinib to treat locally advanced/metastatic cholangiocarcinoma with a FGFR2 fusion that is relapsed or refractory post minimum one line of systemic therapy.
5 Top Value Picks to Counter Recent Stock Market Softness
by Nalak Das
The stable economic fundamentals of the United States have raised the possibility of the recent stock market volatility being a transitory phase and markets continuing their long-term uptrend.
Emergent Biosolutions (EBS) Down 4.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
EBS or ILMN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EBS vs. ILMN: Which Stock Is the Better Value Option?
Emergent (EBS) Beat Earnings in Q3, Vaccines Drive Sales
by Zacks Equity Research
Emergent (EBS) rides high on both earnings and revenues beat in the third quarter. ACAM2000 and Narcan drive revenues.
Emergent Biosolutions (EBS) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of 92.06% and 14.49%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Emergent Biosolutions (EBS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Emergent's Chikungunya Vaccine Candidate Gets EMA's PRIME Tag
by Zacks Equity Research
Emergent's (EBS) chikungunya vaccine candidate CHIKV VLP gains the PRIME status from the Committee for Medicinal Products for Human Use in Europe.
Emergent's Vaccine Profile Boosts Sales Despite Stiff Rivalry
by Zacks Equity Research
Emergent's (EBS) vaccine portfolio holds great potential with the newly-acquired Narcan nasal spray progressing well. Severe rivalry remains a concern though.
Company News For Sep 4, 2019
by Zacks Equity Research
Companies in the news are: CONN, MDCO, EBS and RCL
Emergent Biosolutions (EBS) Down 0.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.